Skip to content

HBV/HCV/HIV in Belgian Prisons

Prevalence of Blood Borne Viral Infections (HBV/HCV/HIV) in the Belgian Prison System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04366492
Enrollment
3045
Registered
2020-04-29
Start date
2019-04-01
Completion date
2020-03-31
Last updated
2020-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B, Hepatitis C, HIV Infections

Brief summary

To assess the prevalence of blood-borne viral infections in prisons in Belgium, screening will be executed in several prisons in Flanders, Brussels and Wallonia to obtain a geographical representative distribution. Upon informed consent screening will be performed using whole capillary blood (finger prick testing) with three different tests for HCV Ab, HBsAg and HIV. Screening will be performed first. While awaiting the test result (15-20min), the participant can fill out a questionnaire (together with the study nurse), concerning risk factors for HCV, HBV and HIV infection. This questionnaire is filled out directly online, and will be immediately implemented in the encoded database. The database is set-up according to the rules of good clinical practice. (Castor EDC software). The results will be filled out immediately by the prison staff in this database after it is filled out by the participant, minimizing the risk of displacement of test results.

Interventions

OTHERPrevalence of blood borne viral infections (HBV/HCV/HIV)

rapid finger prick test for HCV Ab, HBsAg and HIV and a questionnaire

Sponsors

University Ghent
CollaboratorOTHER
Hasselt University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age ≥ 18 years * Imprisoned in one of the predefined prisons in Flanders Brussels or Wallonia participating in this trial * Written informed consent obtained

Exclusion criteria

* Written informed consent not possible: (language barrier, illiteracy) * Already participated in the study: re-entry within inclusion period in one of the prisons

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with HCV Ab+ (Hepatitis C Virus Antibody)day 1test using whole capillary blood (finger prick testing)
Number of participants with HBsAg+ (Hepatitis B surface Antigen)day 1test using whole capillary blood (finger prick testing)
Number of participants with HIV Ab+ (human immunodeficiency virus antibody)day1test using whole capillary blood (finger prick testing)

Secondary

MeasureTime frameDescription
.Prevalence of blood-borne viral infections in Belgian prisonsday 1number of HCV Ab+/number of screened prisoners by finger prick * number of HBsAg+/number of screened prisoners by finger prick * number of HIV Ab+/number of screened prisoners by finger prick
Analysis of uptake of anti(retro)viral treatmentday 1percentage of positive clients who started treatment in relation of total of positive clients needing treatment
5. Questionnaire to Identify risk factors associated with the aforementioned blood borne viral infections (hepatitis C, hepatitis B and HIV) in prisonday 1i. Combine results from positive finger prick test with questionnaire regarding sociodemographic factors, migration, risk factors for blood born viruses (sexual contacts, incarceration, drug use)
Analysis of uptake counselling by physician in prisonday 1Percentage of patients with a positive finger prick test who attend a consultation by the prison physician in relation of total tested positive on finger prick

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026